Among these, EGFR, PDGFR, and VEGFR inhibitors have shown less advantages for their limitations compared to GSC pathways, such as Notch, Wnt, and SHH pathways, suggesting that targeting GSC pathways might become a future direction and an excellent solution in GBM therapy. This evidence concerns the gene KDR and glioblastoma.